Cromwell Holdings LLC Sells 3,801 Shares of Pfizer Inc. $PFE

Cromwell Holdings LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 20.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,732 shares of the biopharmaceutical company’s stock after selling 3,801 shares during the period. Cromwell Holdings LLC’s holdings in Pfizer were worth $357,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Pacer Advisors Inc. grew its holdings in Pfizer by 856.8% in the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock worth $508,164,000 after purchasing an additional 17,957,928 shares during the period. Amundi grew its holdings in Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares during the period. Nuveen LLC acquired a new stake in Pfizer in the first quarter worth $389,861,000. Goldman Sachs Group Inc. grew its holdings in shares of Pfizer by 51.9% during the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after buying an additional 9,041,990 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Pfizer by 307.5% during the first quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company’s stock valued at $254,574,000 after buying an additional 7,581,030 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.5%

Shares of NYSE:PFE opened at $27.08 on Friday. The firm has a fifty day moving average price of $24.62 and a two-hundred day moving average price of $24.14. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The company has a market cap of $153.94 billion, a price-to-earnings ratio of 14.40, a PEG ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period last year, the firm earned $0.60 EPS. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. UBS Group reiterated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday. Bank of America boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Morgan Stanley boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $28.29.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.